Affimed N.V.

9.51+0.0300+0.32%Vol 2.31M1Y Perf 342.13%
Apr 16th, 2021 16:00 DELAYED
BID9.50 ASK9.52
Open9.56 Previous Close9.48
Pre-Market- After-Market9.51
 - -  - -%
Target Price
13.00 
Analyst Rating
Strong Buy 1.00
Potential %
36.70 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★+     48.92
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     59.86
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap839.98M 
Earnings Rating
Buy
Price Range Ratio 52W %
85.63 
Earnings Date
27th Apr 2021

Today's Price Range

9.159.60

52W Range

1.8810.79

5 Year PE Ratio Range

-426.50-2.90

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-2.36%
1 Month
13.48%
3 Months
38.23%
6 Months
167.89%
1 Year
342.13%
3 Years
342.33%
5 Years
114.67%
10 Years
-

TickerPriceChg.Chg.%
AFMD9.510.03000.32
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
2.20
2.20
0.01
0.05
-156.90
Leverage Ratio 2.40
ProfitabilityValueIndustryS&P 500US Markets
-
-174.10
-169.30
-551.90
-
RevenueValueIndustryS&P 500US Markets
16.16M
0.14
86.19
29.48
Earnings HistoryEstimateReportedSurprise %
Q03 2020-0.12-0.0833.33
Q02 2020-0.12-0.18-50.00
Q01 2020-0.11-0.12-9.09
Q04 2019--0.21-
Q03 2019-0.14-0.19-35.71
Q02 2019-0.16-0.160.00
Q01 2019-0.160.03118.75
Q04 2018-0.170.17200.00
Earnings Per EndEstimateRevision %Trend
12/2020 FY-0.38--
3/2021 QR-0.0489.47Positive
6/2021 QR-0.0572.22Positive
12/2021 FY-0.25--
Next Report Date27th Apr 2021
Estimated EPS Next Report-
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume2.31M
Shares Outstanding88.33M
Trades Count16.62K
Dollar Volume9.60M
Avg. Volume3.27M
Avg. Weekly Volume5.85M
Avg. Monthly Volume6.57M
Avg. Quarterly Volume3.43M

Affimed N.V. (NASDAQ: AFMD) stock closed at 9.51 per share at the end of the most recent trading day (a 0.32% change compared to the prior day closing price) with a volume of 2.31M shares and market capitalization of 839.98M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 128 people. Affimed N.V. CEO is Adi Hoess.

The one-year performance of Affimed N.V. stock is 342.13%, while year-to-date (YTD) performance is 63.4%. AFMD stock has a five-year performance of 114.67%. Its 52-week range is between 1.88 and 10.79, which gives AFMD stock a 52-week price range ratio of 85.63%

Affimed N.V. currently has a PE ratio of -13.00, a price-to-book (PB) ratio of 16.22, a price-to-sale (PS) ratio of 69.17, a price to cashflow ratio of 2.00, a PEG ratio of 2.32, a ROA of -40.81%, a ROC of -104.04% and a ROE of -114.04%. The company’s profit margin is -%, its EBITDA margin is -169.30%, and its revenue ttm is $16.16 Million , which makes it $0.14 revenue per share.

Of the last four earnings reports from Affimed N.V., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Affimed N.V.’s next earnings report date is 27th Apr 2021.

The consensus rating of Wall Street analysts for Affimed N.V. is Strong Buy (1), with a target price of $13, which is +36.70% compared to the current price. The earnings rating for Affimed N.V. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Affimed N.V. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Affimed N.V. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.28, ATR14 : 0.59, CCI20 : 78.46, Chaikin Money Flow : -0.22, MACD : 0.90, Money Flow Index : 84.36, ROC : 29.56, RSI : 43.45, STOCH (14,3) : 64.93, STOCH RSI : 0.33, UO : 51.98, Williams %R : -35.07), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Affimed N.V. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Affimed N.V.

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.

CEO: Adi Hoess

Telephone: +49 6221674360

Address: Im Neuenheimer Feld 582, Heidelberg 69120, , DE

Number of employees: 128

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

56%44%

Bearish Bullish

67%33%

Bearish Bullish

58%42%

News

Stocktwits